NDPD Pharma

NDPD Pharma is a South Korean biotechnology company specializing in the development of targeted protein degradation (TPD) therapies for neurodegenerative diseases. Founded in 2020, the company focuses on eliminating pathogenic protein aggregates, such as alpha-synuclein and tau, which are central to the progression of Parkinson's and Alzheimer's diseases. Their proprietary platform is designed to create brain-penetrant small molecule degraders that offer a potential advantage over traditional monoclonal antibodies. NDPD Pharma's lead program, NDPD-001, is currently in preclinical development for the treatment of Parkinson's disease. By leveraging the body's natural protein disposal system, the company aims to provide disease-modifying solutions for patients suffering from debilitating neurological conditions. The company is supported by prominent Korean venture capital firms and continues to expand its pipeline into other protein-misfolding disorders.